EUVIMEDEUVIMED entdecken
Crossref

Selenium serves as an immunomodulator adjunct to enhance the efficacy of anti-PD-1 therapy in non-small cell lung cancer

Kaiyuan Guo, Hongwei Hu, Naichen Yao, Qitai Zhao iD, Shasha Liu, Peng Wu, Yachang Huo, Pingchuan Ma, Tianran Chen, Xinfeng Chen, Guohui Qin, Yi Zhang iD

The Journal of Immunology · 2026

DOI: 10.1093/jimmun/vkag241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Kaiyuan Guo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Selenium, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Programmed Cell Death 1 Receptor. Die Arbeit nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Intergovernmental International Science and Technology Innovation Cooperation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of selenium in tumor progression remains controversial, and its mechanisms of action in the context of immunotherapy are poorly understood. In this study, our findings indicate that selenium supplementation did not alter immune parameters, induce organ damage under healthy conditions, or affect the growth of Lewis lung cancer cells in vitro. In tumor-bearing mice, although selenium supplementation alone significantly enhanced the infiltration of CD8+ T cells into tumors, it failed to arrest tumor growth. Further analyses revealed that selenium treatment upregulated the expression of PD-1 on CD8+ T cells and PD-L1 on tumor cells. This finding suggests that PD-1/PD-L1 engagement may impair CD8+ T cell function, thereby preventing the effective elimination of tumor cells. Consequently, selenium supplementation exhibited a strong synergistic effect when combined with anti-PD-1 therapy, yielding enhanced antitumor responses. Single-cell RNA sequencing analysis revealed that the CD8-Prf1 subpopulation expanded and displayed enhanced proliferative and cytotoxic gene signatures after treatment with a combination of selenium and anti-PD-1. Clinically, a high abundance of this subpopulation was associated with prolonged survival in patients receiving anti-PD-1 treatment. Our results indicate that selenium is a promising immunomodulator adjunct that augments CD8+ T cell function and improves the response to anti-PD-1 therapy, supporting further clinical investigation of selenium supplementation in combination with immune checkpoint inhibitors for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SeleniumCarcinoma, Non-Small-Cell LungLung NeoplasmsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsImmunomodulating AgentsAnimalsMiceCD8-Positive T-LymphocytesHumansCell Line, TumorCarcinoma, Lewis LungMice, Inbred C57BLFemale

Stichwörter der Autor:innen

combination therapyimmune checkpoint inhibitorsnon-small cell lung cancerselenium

Substanzen

SeleniumProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsImmunomodulating Agents

Autor:innen und Institutionen

  • Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • School of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
  • School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China.
  • State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan…
  • Zhongyuan Cell Therapy and Immunotherapy Laboratory, Henan Academy of Innovations in Medical Science, Zhengzhou, China.

ORCID-Profile: Qitai Zhao, Yi Zhang

Förderung

  • National Natural Science Foundation of China
  • Intergovernmental International Science and Technology Innovation Cooperation Project

Zitieren

APA

Guo, K., Hu, H., Yao, N., Zhao, Q., Liu, S., Wu, P., Huo, Y., Ma, P., Chen, T., Chen, X., Qin, G., & Zhang, Y. (2026). Selenium serves as an immunomodulator adjunct to enhance the efficacy of anti-PD-1 therapy in non-small cell lung cancer. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag241

Vancouver

Guo K, Hu H, Yao N, Zhao Q, Liu S, Wu P, et al. Selenium serves as an immunomodulator adjunct to enhance the efficacy of anti-PD-1 therapy in non-small cell lung cancer. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag241

BibTeX
@article{Guo2026,
  author = {Guo, Kaiyuan and Hu, Hongwei and Yao, Naichen and Zhao, Qitai and Liu, Shasha and Wu, Peng and Huo, Yachang and Ma, Pingchuan and Chen, Tianran and Chen, Xinfeng and Qin, Guohui and Zhang, Yi},
  title = {Selenium serves as an immunomodulator adjunct to enhance the efficacy of anti-PD-1 therapy in non-small cell lung cancer},
  journal = {The Journal of Immunology},
  year = {2026},
  doi = {10.1093/jimmun/vkag241}
}
Kostenlos starten →